FDA approves first drug for spinal muscular atrophy

By December 23, 2016 FDA Press Releases No Comments

The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Spinraza is an injection administered into the fluid surrounding the spinal cord.
Source: FDA Press Releases